ArticleMolecular biology reports2026
LINC00265 is significantly upregulated in breast carcinoma: expression, correlation networks, and potential prognostic value.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral signaling pathways and related transcripts have been found to be dysregulated in breast cancer. Methods and Results: In this study, we used an in silico step aiming to find the most relevant biological pathways and related long non-coding RNAs (lncRNAs) in the pathoetiology of breast cancer. This step led to identification of EGFR and its related lncRNAs as contributors to the pathology of this type of cancer. Then, we assessed expression of these transcripts in breast cancer samples and their adjacent non-cancerous tissues (ANCTs). Among the assessed transcripts, LINC00265 was markedly upregulated in tumor tissues, exhibiting a mean fold-change of 3.26 (95% CI 1.28–8.23; P = 0.017). The results of correlation analyses revealed that in ANCTs, LINC00265 expression aligned with EGFR and two lncRNAs (ZEB1-AS1 and PITPNA-AS1), whereas in carcinoma the regulatory network shifted—LINC00265 decoupled from the other genes, and EGFR, ZEB1-AS1 and PITPNA-AS1 formed a tightly co-regulated module. ROC curve analyses indicated that among the transcripts tested, LINC00265 exhibited the most promising sensitivity for tumor detection, whereas ZEB1-AS1 provided greater specificity. Conclusions: Taken together, our data demonstrated up-regulation of LINC00265 in breast cancer tissues independent of standard clinicopathologic parameters and co-expressed transcripts in this cohort of patients. Further studies are needed to confirm these results in larger cohorts of patients.
Indexed as
Identifiers
41604036What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.